Skip to content
← Full study record

NCT00102804 · MORE INFO

Limitations, agreements, and source contact

Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2014-12-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
GT60
restrictive Agreement
true
limitations And Caveats
description
Four participants (pts) assigned to placebo received pemetrexed; pts analyzed for efficacy as randomized. Three treated pts did not sign ICF, 1 treated pt signed ICF but did not complete entire randomization process; pts excluded from all analyses.
point Of Contact
organization
Eli Lilly and Company
phone
800-545-5979
title
Chief Medical Officer
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
GT60
restrictive Agreement
true
limitations And Caveats
description
Four participants (pts) assigned to placebo received pemetrexed; pts analyzed for efficacy as randomized. Three treated pts did not sign ICF, 1 treated pt signed ICF but did not complete entire randomization process; pts excluded from all analyses.
point Of Contact
organization
Eli Lilly and Company
phone
800-545-5979
title
Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice